Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pasithea Therapeutics (KTTA) Non-cash Items (2021 - 2024)

Pasithea Therapeutics (KTTA) has disclosed Non-cash Items for 4 consecutive years, with $95514.0 as the latest value for Q3 2024.

  • Quarterly Non-cash Items fell 88.71% to $95514.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $95514.0 through Sep 2024, down 88.71% year-over-year, with the annual reading at $55500.0 for FY2023, 412.32% up from the prior year.
  • Non-cash Items hit $95514.0 in Q3 2024 for Pasithea Therapeutics, down from $103038.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $845835.0 in Q3 2023 to a low of $10833.0 in Q4 2022.
  • Historically, Non-cash Items has averaged $175898.7 across 4 years, with a median of $100000.0 in 2021.
  • Biggest five-year swings in Non-cash Items: crashed 89.17% in 2022 and later soared 412.32% in 2023.
  • Year by year, Non-cash Items stood at $100000.0 in 2021, then plummeted by 89.17% to $10833.0 in 2022, then skyrocketed by 412.32% to $55500.0 in 2023, then soared by 72.1% to $95514.0 in 2024.
  • Business Quant data shows Non-cash Items for KTTA at $95514.0 in Q3 2024, $103038.0 in Q2 2024, and $98267.0 in Q1 2024.